Efficacy of Botulinum Toxin Type A Injection on Masseter Hypertrophy
Keywords:
Botulinum Toxin, Hypertrophy, Masseter Hypertrophy, Visual Analogue ScaleAbstract
Background and Objectives: Masseter hypertrophy (MH) is characterized by abnormalenlargement of the masseter muscle (MM), leading to aesthetic concerns and functional
impairment. This study aimed to evaluate the clinical efficacy and safety of botulinum toxin type
A (BTX-A) injections for the reduction of masseter muscle hypertrophy (MMH).
Methods: A prospective clinical study was carried out in the Maxillofacial Department of
Rizgary Teaching Hospital from February 2018 to August 2019 and 19 patients were included
who were suffering from MH. The condition was clinically diagnosed. With the diluted BTX
A (30IU in ringer lactates injected at five masseter points, 6 iu each points ), Pre-injection and
post-injection performance measurements were performed at 12 weeks on a patient-self-reported
scale using a visual analog scale (VAS).
Results: This study's findings indicate that 12 weeks after the administration of BTX-A, there
was a significant efficacy in reducing MMH, with only one patient exhibiting no change in
muscle hypertrophy post-injection but after injection was reduced and one patient . exhibit
herniation
Conclusion: This study established that the use of BTX-A significantly decreased MMH.
These results suggest that BTX-A can be utilized as a safe and risk-free method with maximum
effectiveness in treating MMH.
References
Mattsson J, Carlsson A. Masseter and temporalis muscle thickness as assessed by ultrasound–a
proof-of-concept study.
Almukhtar RM, Fabi SG. The masseter muscle and its role in facial contouring, aging, and
quality of life: a literature review. Plastic and Reconstructive Surgery. 2019 Jan 1;143(1):39e
e.
Pinto AS, GalvÃo ND, Mendes JD, Pinto PH, Lopes SL, Costa AL. Evaluation measure of 3d
volumetry of masseter hypertrophy: association with modalities of imaging. RGO-Revista
Gaúcha de Odontologia. 2018 Oct;66:375-83.
Beaumont S, Garg K, Gokhale A, Heaphy N. Temporomandibular disorder: a practical guide
for dental practitioners in diagnosis and management. Australian Dental Journal. 2020
Sep;65(3):172-80.
Haun CT, Vann CG, Roberts BM, Vigotsky AD, Schoenfeld BJ, Roberts MD. A critical
evaluation of the biological construct skeletal muscle hypertrophy: size matters but so does the
measurement. Frontiers in physiology. 2019 Mar 12;10:247.
Anehosur V, Mehra A, Kumar N. Management of masseter muscle hypertrophy and role of
adjunctive surgical procedures. Craniomaxillofacial Trauma & Reconstruction Open. 2020 Apr
;5:2472751220913147.
Castroflorio T, Bargellini A, Deregibus A, Svensson P. Masticatory muscle pain and
disorders. InContemporary Oral Medicine 2018 Dec 26 (pp. 1-38). Springer Nature Switzerland
AG 2018.
Arora A, Sodhi A, Hegde S, Roy AK. Masseter muscle hypertrophy associated with
temporomandibular joint disorder-A case report. Am J Oral Med Radiol. 2015;2(3):110-4.
Caldas W, Conti AC, Janson G, Conti PC. Occlusal changes secondary to temporomandibular
joint conditions: a critical review and implications for clinical practice. Journal of Applied Oral
Science. 2016;24(4):411-9.
Ayhan M, İşler SC, Kasapoglu C. Combination of medical and surgical treatments for
masseter hypertrophy. Case Reports in Dentistry. 2018;2018(1):7168472.
Lee EI, Kim NH, Park RH, Park JB, Ahn TJ. Botulinum Toxin Type A for Treatment of
Masseter Hypertrophy: Volumetric Analysis of Masseter Muscle Reduction over Time. Archives
of Aesthetic Plastic Surgery. 2016 Jul 8;22(2):79-86.
Kahn A, Bertin H, Corre P, Praud M, Paré A, Kün-Darbois JD. Assessing the effectiveness
of botulinum toxin injections into masticatory muscles in the treatment of temporomandibular
disorders. Journal of Oral Medicine and Oral Surgery. 2018 Oct 1;24(3):107-11.
Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by
adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with
botulinum toxin type a injection. Dermatologic Surgery. 2015 Jan 1;41:S101-9.
Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the
masseter muscle. Plastic and reconstructive surgery. 2010 Jun 1;125(6):1693-705.
Novembre D, Ferragina F, Cordaro R, Cristofaro MG. Efficacy of botulinum toxin type a in
bilateral hypertrophy of masseter and temporalis muscles. A case report. POLICLINICO.
SEZIONE MEDICA. 2020;127(1):1-9.
Mor N, Tang C, Blitzer A. Temporomandibular myofacial pain treated with botulinum toxin
injection. Toxins. 2015 Jul 24;7(8):2791-800.
Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a
literature review of clinical use and pharmacological aspect. Clinical, cosmetic and
investigational dermatology. 2019 Apr 10:223-8.
Tater P, Pandey S. Botulinum toxin in movement disorders. Neurology India. 2018 Mar
;66(Suppl 1):S79-89.
Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with
botulinum toxin type A for the treatment of masseter hypertrophy. Anais brasileiros de
dermatologia. 2014 Nov;89:878-84.
Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in East
Asians. Dermatologic Surgery. 2019 Apr 1;45(4):566-72.
Yeh YT, Peng JH, Peng HL. Literature review of the adverse events associated with
botulinum toxin injection for the masseter muscle hypertrophy. Journal of cosmetic dermatology.
Oct;17(5):675-87.
Tsai CY, Lei YY, Yang LY, Chiu WC. Changes of masseter muscle activity following
injection of botulinum toxin type A in adult rats. Orthodontics & Craniofacial Research. 2015
Nov;18(4):202-11.
Peng HL, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy:
Incidence rate from 2036 treatments and summary of causes and preventions. Journal of
cosmetic dermatology. 2018 Feb;17(1):33-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 University of Thi-Qar Journal Of Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
